Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
A phase 2 trial of durvalumab, tremelimumab, gemcitabine and other drugs in gallbladder cancer and other biliary tract cancers, run by AHS Cancer Control Alberta, now recruiting.
Overview
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) is a phase 2 interventional study registered as NCT05451043 by AHS Cancer Control Alberta, with a registry enrolment figure of 62 participants, started 2023-07-05 and due to reach its primary completion in 2026-10-01. Interventions recorded: Durvalumab, Gemcitabine, Nab paclitaxel, Tremelimumab, Propranolol, Cisplatin. Conditions listed: Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer, Cholangiocarcinoma. Sites: Canada. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialCTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialMP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialDurvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialSafety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialThe Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Gemcitabine and the tag gallbladder-deep-dive.
- TrialMulticenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialGemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialStudy of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.